GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (OTCPK:REPCF) » Definitions » Institutional Ownership

RepliCel Life Sciences (RepliCel Life Sciences) Institutional Ownership : 0.89% (As of May. 17, 2024)


View and export this data going back to 2004. Start your Free Trial

What is RepliCel Life Sciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, RepliCel Life Sciences's institutional ownership is 0.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, RepliCel Life Sciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, RepliCel Life Sciences's Float Percentage Of Total Shares Outstanding is 48.77%.


RepliCel Life Sciences Institutional Ownership Historical Data

The historical data trend for RepliCel Life Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RepliCel Life Sciences Institutional Ownership Chart

RepliCel Life Sciences Historical Data

The historical data trend for RepliCel Life Sciences can be seen below:

2020-01-31 2020-02-29 2020-03-31 2020-04-30 2020-05-31 2020-06-30 2020-07-31 2020-09-30 2020-10-31 2020-11-30
Institutional Ownership 1.07 1.07 1.06 1.06 1.06 1.05 0.94 0.90 0.89 0.89

RepliCel Life Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


RepliCel Life Sciences (RepliCel Life Sciences) Business Description

Traded in Other Exchanges
Address
570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.